PD-L1 expression and clinical outcomes with targeted therapy

A recent study published in Clinical Cancer Research analysed tumour tissue samples obtained in a clinical trial to investigate how the expression of the PD-L1 receptor on the tumour cells influenced outcomes in patients with metastatic renal cell carcinoma (RCC) receiving targeted therapy.

Positive expression of the PD-L1 receptor on RCC tumour cells was associated with shorter progression-free and overall survival compared with negative tumour cell PD-L1 expression when patients were treated with cabozantinib, everolimus or suntinib.

In conclusion, higher PD-L1 expression on RCC tumour cells was associated with inferior clinical outcomes among patients with metastatic RCC treated with targeted therapy.

Read more in Clinical Cancer Research here

Share this Post!


Related post

  TOP